| Item type |
文献 / Documents(1) |
| 公開日 |
2022-08-23 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.1172/JCI151239 |
|
|
関連名称 |
10.1172/JCI151239 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas |
| 著者 |
荻野, 広和
Taylor, Jennie W.
ネジョウ, タカヒデ
Gibson, David
Watchmaker, Payal B.
オカダ, カオリ
西條, 敦郎
Tedesco, Meghan R.
Shai, Anny
Wong, Cynthia M.
Rabbitt, Jane E.
Olin, Michael R.
Moertel, Christopher L.
西岡, 安彦
Salazar, Andres M.
Molinaro, Annette M.
Phillips, Joanna J.
Butowski, Nicholas A.
Clarke, Jennifer L.
Oberheim Bush, Nancy Ann
Hervey-Jumper, Shawn L.
Theodosopoulos, Philip
Chang, Susan M.
Berger, Mitchel S.
オカダ, ヒデホ
|
| 抄録 |
|
|
内容記述 |
BACKGROUND. Long-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy.
METHODS. We conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor.
RESULTS. A total of 17 eligible patients were enrolled — 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident–like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination.
CONCLUSION. The regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies. |
| 書誌情報 |
en : Journal of Clinical Investigation
巻 132,
号 3,
p. e151239,
発行日 2022-02-01
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
00219738 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
15588238 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00695520 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12034468 |
| 出版者 |
|
|
出版者 |
American Society for Clinical Investigation |
| 権利情報 |
|
|
権利情報 |
This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. |
| EID |
|
|
識別子 |
387240 |
| 言語 |
|
|
言語 |
eng |
jci_132_3_e151239.pdf (4.05 MB)
.png)
